Takip et
Veeral Ajmera
Veeral Ajmera
Associate Professor of Medicine, University of California San Diego
ucsd.edu üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis
C Caussy, MH Alquiraish, P Nguyen, C Hernandez, S Cepin, LE Fortney, ...
Hepatology 67 (4), 1348-1359, 2018
2932018
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease
V Ajmera, ER Perito, NM Bass, NA Terrault, KP Yates, R Gill, R Loomba, ...
Hepatology 65 (1), 65-77, 2017
1682017
Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD
C Caussy, C Hsu, MT Lo, A Liu, R Bettencourt, VH Ajmera, S Bassirian, ...
Hepatology 68 (3), 918-932, 2018
1672018
Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function
SR Sharpton, V Ajmera, R Loomba
Clinical Gastroenterology and Hepatology 17 (2), 296-306, 2019
1462019
Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease
V Ajmera, CC Park, C Caussy, S Singh, C Hernandez, R Bettencourt, ...
Gastroenterology 155 (2), 307-310. e2, 2018
1402018
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
VH Ajmera, NA Terrault, SA Harrison
Hepatology 65 (6), 2090-2099, 2017
1302017
Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis
V Ajmera, P Belt, LA Wilson, RM Gill, R Loomba, DE Kleiner, ...
Clinical Gastroenterology and Hepatology 16 (9), 1511-1520. e5, 2018
1262018
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial
R Loomba, R Mohseni, KJ Lucas, JA Gutierrez, RG Perry, JF Trotter, ...
Gastroenterology 161 (5), 1475-1486, 2021
1172021
Imaging biomarkers of NAFLD, NASH, and fibrosis
V Ajmera, R Loomba
Molecular metabolism 50, 101167, 2021
1052021
Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease
VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ...
Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016
1032016
Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease
VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ...
Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016
1022016
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
N Tamaki, V Ajmera, R Loomba
Nature Reviews Endocrinology 18 (1), 55-66, 2022
972022
What factors determine the severity of hepatitis A‐related acute liver failure?
V Ajmera, G Xia, G Vaughan, JC Forbi, LM Ganova‐Raeva, Y Khudyakov, ...
Journal of viral hepatitis 18 (7), e167-e174, 2011
852011
Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene–environment interaction study
CA Emdin, M Haas, V Ajmera, TG Simon, J Homburger, C Neben, L Jiang, ...
Gastroenterology 160 (5), 1620-1633. e13, 2021
822021
Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease
LB VanWagner, H Ning, NB Allen, V Ajmera, CE Lewis, JJ Carr, ...
Gastroenterology 153 (5), 1260-1272. e3, 2017
742017
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
V Ajmera, S Cepin, K Tesfai, H Hofflich, K Cadman, S Lopez, E Madamba, ...
Journal of Hepatology 78 (3), 471-478, 2023
722023
Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease
VH Ajmera, A Liu, S Singh, G Yachoa, M Ramey, M Bhargava, A Zamani, ...
Hepatology 71 (3), 849-860, 2020
642020
Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women
VH Ajmera, NA Terrault, LB VanWagner, M Sarkar, CE Lewis, JJ Carr, ...
Journal of hepatology 70 (1), 126-132, 2019
612019
Machine learning enables new insights into genetic contributions to liver fat accumulation
ME Haas, JP Pirruccello, SN Friedman, M Wang, CA Emdin, VH Ajmera, ...
Cell genomics 1 (3), 2021
592021
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
C Caussy, VH Ajmera, P Puri, CLS Hsu, S Bassirian, M Mgdsyan, S Singh, ...
Gut 68 (10), 1884-1892, 2019
592019
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20